Mirati Therapeutics, Inc.
9393 Towne Centre Drive
Suite 200
San Diego, CA 92121
United States
858 332 3410
http://www.mirati.com
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 111
Figure dirigenziali chiave
| Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
|---|---|---|---|---|
| Dr. Charles M. Baum | Pres, CEO & Director | 1,01M | N/D | 1958 |
| Dr. James G. Christensen | Chief Scientific Officer & Exec. VP | 655k | N/D | 1968 |
| Mr. Daniel R. Faga | Exec. VP, COO & Principal Financial Officer | N/D | N/D | 1980 |
| Ms. Vickie S. Reed | Sr. VP of Technical Operation & Chief Accounting Officer | N/D | N/D | 1962 |
| Temre Johnson | Director of Investor Relations & Corp. Communications | N/D | N/D | N/D |
| Ms. Reena R. Desai | VP, Gen. Counsel & Corp. Sec. | N/D | N/D | N/D |
| Mr. Matthew Marx | VP & Head of Drug Discovery | N/D | N/D | N/D |
| Mr. Philip Roberts | Sr. VP of Technical Operations | N/D | N/D | N/D |
| Mr. Benjamin J. Hickey | Exec. VP & Chief Commercial Officer | N/D | N/D | 1975 |
| Dr. Kelly Covello Ph.D. | VP & Head of Medical Affairs | N/D | N/D | N/D |
Descrizione
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. It is developing MRTX849, a KRAS G12C inhibitor, which is in Phase I/II clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and sitravatinib, a spectrum-selective kinase inhibitor that is in Phase II clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. The company has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and a clinical collaboration agreement with Novartis Pharmaceuticals Corporation. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.
Governance aziendale
L'ISS Governance QualityScore di Mirati Therapeutics, Inc. al 6 ottobre 2020 è 5. I criteri di valutazione fondamentali sono revisione: 2; Consiglio di Amministrazione: 5; diritti degli azionisti: 4; retribuzione: 8.
